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 27 
ABSTRACT 28 
Objectives: PYRRO-C3D is a cephalosporin-3-diazeniumdiolate nitric oxide (NO)-donor 29 
prodrug designed to selectively deliver NO to bacterial infection sites. The objective of this 30 
study was to assess the activity of PYRRO-C3D against non-typeable Haemophilus influenzae 31 
(NTHi) biofilms and examine the role of NO in reducing biofilm-associated antibiotic 32 
tolerance.  33 
 34 
Methods: The activity of PYRRO-C3D on in vitro NTHi biofilms was assessed through CFU 35 
enumeration and confocal microscopy. NO release measurements were performed using an 36 
ISO-NO probe. NTHi biofilms grown on primary ciliated respiratory epithelia at an air-liquid 37 
interface were used to investigate the effects of PYRRO-C3D in the presence of host tissue. 38 
Label-free LC/MS proteomic analyses were performed to identify differentially expressed 39 
proteins following NO treatment. 40 
 41 
Results: PYRRO-C3D specifically released NO in the presence of NTHi, while no evidence of 42 
spontaneous NO release was observed when the compound was exposed to primary 43 
epithelial cells. NTHi lacking β-lactamase activity failed to trigger NO release. Treatment 44 
significantly increased the susceptibility of in vitro NTHi biofilms to azithromycin, causing a 45 
log-fold reduction in viability (p<0.05) relative to azithromycin alone. The response was 46 
more pronounced for biofilms grown on primary respiratory epithelia, where a 2-log 47 
reduction was observed (p<0.01). Label-free proteomics showed that NO increased 48 
expression of sixteen proteins involved in metabolic and transcriptional/translational 49 
functions. 50 
 51 
  
Conclusions: NO release from PYRRO-C3D enhances the efficacy of azithromycin against 52 
NTHi biofilms, putatively via modulation of NTHi metabolic activity. Adjunctive therapy with 53 
NO mediated through PYRRO-C3D represents a promising approach for reducing biofilm-54 
associated antibiotic tolerance. 55 
 56 
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1. INTRODUCTION  60 
Non-typeable Haemophilus influenzae (NTHi) plays a major role in a number of 61 
chronic lung diseases, including chronic obstructive pulmonary disease, the fourth largest 62 
cause of mortality worldwide [1], and cystic fibrosis, where early childhood infection leads to 63 
an environment within the lung that is more susceptible to infection by Pseudomonas 64 
aeruginosa [2]. NTHi is also the predominant early coloniser in primary ciliary dyskinesia 65 
(PCD), another genetic chronic lung disease characterised by a lack of mucociliary clearance, 66 
chronic lung infection and lung function decline [3,4].   67 
Persistence of NTHi infection is often associated with biofilm formation, with NTHi 68 
biofilms being implicated in a number of clinical settings including formation on middle ear 69 
epithelium during chronic otitis media [5], chronic rhinosinusitis [6], chronic obstructive 70 
pulmonary disease (COPD) sputum [7], and lower respiratory tract diseases [8]. The biofilm 71 
phenotype enables bacteria to evade the host immune response, benefit from increased 72 
antibiotic tolerance, and subsequently develop antibiotic resistance through horizontal gene 73 
transfer [9]. Exopolysaccharide matrix formation by biofilm bacteria may also restrict the 74 
diffusion of antibiotics into biofilms and prevent ingress of immune cells [10]. Increased 75 
expression of efflux pumps and β-lactamases have also been shown to contribute to 76 
increased tolerance. It is the change to a metabolically dormant phenotype, however, that 77 
potentially plays the most important role, rendering antibiotics that target cell division 78 
ineffective [11]. Biofilm formation in NTHi has been associated with the reduced metabolic 79 
activity typical of that observed in other bacterial species, with preserved ability to respond 80 
to stress [12]. As well as clinical isolates from a range of diseases having the ability to form in 81 
vitro biofilms [8], NTHi has also been shown to form biofilms on cultured respiratory 82 
epithelial surfaces with decreased antibiotic susceptibility [13,14].  NTHi biofilms also exhibit 83 
quorum signalling that is characteristic of other respiratory biofilm formers such as P. 84 
aeruginosa [15].  Whilst P. aeruginosa is the most widely studied biofilm forming respiratory 85 
  
pathogen, many differences exist with NTHi.  For example, P. aeruginosa biofilms form 86 
within mucus in vivo [16] rather than attached to the epithelial surface as NTHi biofilms do 87 
[5,6,13,14]. Also, cyclic-di-GMP seems to play a pivotal role in the P. aeruginosa biofilm life 88 
cycle under the control of guanylate cyclases and phosphodiesterases [17], however NTHi 89 
genome sequencing shows no domains coding for these enzymes [18]. 90 
Bacteria within biofilms can be triggered by various external factors to revert to a 91 
planktonic single cell state, a process that not only facilitates propagation and re-92 
colonisation elsewhere within the host but also renders the bacteria more susceptible to 93 
antibiotics [10]. Development of a therapeutic approach that induces dispersal or reverses 94 
the metabolically dormant phenotype is therefore an attractive approach for improving 95 
antibiotic effectiveness in the treatment of biofilm-associated infections. 96 
 Nitric oxide (NO) is a ubiquitous signalling molecule that plays a wide range of 97 
biological roles in both prokaryotes and eukaryotes. Low dose NO has been shown to signal 98 
a dispersal response in biofilms formed by a number of bacterial species, including P. 99 
aeruginosa, Escherichia coli, Serratia marcascens, Staphylococcus aureus, and also multi-100 
species biofilms [19-21]. However, NO also plays a number of important roles in the human 101 
host, meaning that administration of spontaneous NO donors as drugs would likely elicit 102 
undesirable side effects, particularly through alterations in circulatory dynamics [22-24]. To 103 
address this we have developed a novel class of targeted NO prodrugs (cephalosporin-3’-104 
diazeniumdiolates) that are composed of a diazeniumdiolate (NONOate) NO-donor attached 105 
to the 3’-position of first generation cephalosporins. This innovative drug class was designed 106 
to selectively release the NONOate following cleavage of the β-lactam ring by bacterial β-107 
lactamases, thereby targeting NO delivery directly to the site of infection [25] (Figure 1a). 108 
We hypothesised that treatment of NTHi biofilms with a cephalosporin-3’-diazeniumdiolate 109 
(i.e. PYRRO-C3D K+ salt, Figure 1a) would signal a return to a planktonic phenotype, thereby 110 
increasing NTHi sensitivity towards conventional antibiotics. We investigated the activity of 111 
  
PYRRO-C3D, both alone and in combination with azithromycin, on biofilms formed in vitro 112 
and on primary respiratory epithelia grown at an air-liquid interface. High-throughput label-113 
free proteomic analyses were performed to provide mechanistic insights into the role of NO 114 
in NTHi biofilms. 115 
 116 
2. MATERIALS AND METHODS 117 
2.1 Ethics 118 
Local and national R&D and ethical approvals were obtained (Southampton and South West 119 
Hampshire Research Ethics 06/Q1704/105 and 07/Q1702/109). 120 
 121 
2.2 Bacterial strains and growth conditions 122 
NTHi strain HI4 was isolated from the sputum of a PCD patient. HI5 and HI6 were from nasal 123 
swabs of healthy children participating in a nasal carriage study. All experiments were 124 
performed using strain HI4 unless stated otherwise. HI4 and HI6 were β-lactamase 125 
producing strains, whilst HI5 lacked β-lactamase activity. Strains were subcultured onto 126 
Colombia agar with chocolated horse blood (CBA; Oxoid, U.K.) and grown at 37 oC and 5% 127 
CO2. Colonies were resuspended in brain-heart infusion (BHI) broth (Oxoid, U.K.) 128 
supplemented with 10 μg/mL hemin and 2 μg/mL nicotinamide adenine dinucleotide.  129 
 130 
2.3 Planktonic experiments 131 
Flat-bottomed 96-well culture plates (Fisher Scientific, U.K.) were inoculated with ~1.0 x 107 132 
mid-exponential NTHi grown in supplemented BHI. 10 mM PYRRO-C3D (in DMSO) was 133 
diluted in supplemented BHI and added to wells at final concentrations of 1 - 200 μM, with 134 
supplemented BHI used as an untreated control. Cultures were incubated at 37 oC and 5% 135 
CO2 for 24 h. Absorbance (OD595) was measured using an EZ Read 400 spectrophotometer 136 
(Biochrom; n=3). 137 
  
 138 
2.4 In vitro biofilm experiments 139 
Untreated polystyrene 6-well tissue culture plates (Corning Incorporated, U.S.A.) were 140 
inoculated with ~2.0 x 108 mid-exponential NTHi grown in supplemented BHI. Plates were 141 
incubated at 37 oC and 5 % CO2 for 72 h and media replaced with fresh supplemented BHI 142 
daily. Biofilms were then washed twice with Hanks’ Balanced Salt Solution (HBSS) to remove 143 
unattached cells before being treated with 10 nM - 100 μM PYRRO-C3D, 50 μM each of 144 
carboxy-PTIO (cPTIO), DEA/NO, clavulanate and cephaloram, and 4 mg/mL azithromycin for 145 
2 hours at 37 oC and 5 % CO2. Biofilms were washed twice then resuspended in 1 mL HBSS, 146 
vortexed, then serial diluted before being spot plated onto CBA and incubated at 37 oC and 5% 147 
CO2. For confocal imaging, biofilms were grown on 35 mm untreated glass bottom CELLview 148 
culture dishes (Greiner Bio One, U.K.) and prepared as above. Following treatment, biofilms 149 
were stained with a Live/Dead BacLight bacterial viability kit (Life Technologies, U.S.A.) as 150 
per manufacturer’s instructions and examined using a Leica SP8 Laser confocal scanning 151 
microscope (LCSM) with inverted stand under a 63x oil immersion lens. Sequential scanning 152 
was performed using 1 μm sections and the images analysed using Comstat 2.0 software 153 
[26]. 154 
 155 
2.5 Epithelial cell co-culture experiments 156 
Nasal epithelial cells were obtained from healthy volunteers, cultured through two passages, 157 
then placed on 12 mm transwells (0.4 μm pore size) as previously described [27]. Once 158 
confluent, apical media was removed and the cells fed at the baso-lateral surface every 48 h. 159 
A minimum of 4 weeks after ciliation, trans-epithelial resistance was measured to confirm an 160 
intact epithelial surface [28]. NTHi in MEM containing HEPES without glutamine 161 
(ThermoFisher, U.K.) were applied to the apical surface of the epithelial cells at an MOI of 162 
100:1. Co-cultures were grown for 72 h at 37 oC and 5% CO2 with the media changed every 163 
  
24 h. Both the apical and baso-lateral surfaces were washed with HBSS prior to treatment. 164 
Co-cultures were treated with compounds and processed for CFU enumeration as before. 165 
Transwell membranes were removed, processed as previously described [29], and remaining 166 
biofilms imaged using an FEI Quanta 250 scanning electron microscope. 167 
 168 
2.6 Nitric oxide measurements 169 
Nitric oxide release from 50 μM PYRRO-C3D in phosphate buffered saline (PBS) was 170 
measured using an ISO-NO probe (World Precision Instruments, U.S.A.) as per the 171 
manufacturer’s instructions. PYRRO-C3D was activated through addition of Bacillus cereus 172 
penicillinase (10 units, Sigma, U.K.) and NO release recorded over 130 minutes. NO release 173 
from PYRRO-C3D in the presence of mid-exponential NTHi cells was measured for 15 mins 174 
before quenching the reaction with 50 μM clavulanate (β-lactamase inhibitor). For epithelial 175 
cell co-culture measurements, 750 μL PBS was added to the apical surface and the probe 176 
inserted. Baseline NO release was measured for 30 mins before activating PYRRO-C3D 177 
through addition of 10 units of B. cereus penicillinase. 178 
 179 
2.7 Proteomic analysis 180 
An alternative NO-donor (sodium dinitroprusside, SNP) was used in place of PYRRO-C3D to 181 
characterise the response of NTHi biofilms to NO, without being confounded by any activity 182 
arising from the β-lactam component of PYRRO-C3D [30]. Untreated and 50 μM SNP treated 183 
in vitro NTHi4 biofilms were resuspended in 1 mL HBSS and washed twice by centrifugation 184 
at 10,000 xg for 5 mins at 4 oC. The supernatant was discarded, the pellet resuspended in 185 
digestion buffer containing 4 M guanidine hydrochloride, 10 mg/mL lysozyme, and 100 mM 186 
triethylammonium bicarbonate (TEAB) prepared in HBSS, and incubated at 37 oC for 30 mins. 187 
Samples were bead beaten with 0.1 mm zirconium oxide beads at 50 Hz for 5 minutes, 188 
centrifuged at 3,000 xg for 2 mins at room temperature, and the supernatants filter 189 
  
sterilized through 0.22 μm polyethersulfone membranes to remove any remaining intact 190 
cells. Samples were precipitated overnight in 100% ethanol at -20 oC, centrifuged at 12,000 191 
xg for 5 mins at 4oC, and resuspended in 100 mM TEAB with 0.1% Rapigest SF surfactant 192 
(Waters, U.K.). Protein solutions were heat treated at 80 oC for 10 mins and then briefly 193 
vortexed. DTT (in 100 mM TEAB) was added to a final concentration of 2.5 nM then heat 194 
treated at 60 oC for 10 mins.  After cooling, the solution was spun at 10,000 xg and 195 
iodoacetamide was added at a final concentration of 7.5 mM before incubating at room 196 
temperature for 30 mins in the dark. Protein samples were digested in trypsin solution 197 
overnight at 37 oC. Trifluoroacetic acid was added to a final concentration of 0.5% and the 198 
mixtures incubated for 30 minutes at 37 oC, before being centrifuged at 13,000 xg for 10 199 
mins.  The supernatant was lyophilised and resuspended in 200 mM ammonium formate 200 
with 100 fmol of enolase as internal standard. 201 
 202 
2.7.1 Mass spectrometry of NTHi biofilm protein samples 203 
Peptide separations were performed using a nanoAcquity UPLC system (Waters, U.K.). For 204 
the first dimension separation, 1.0 µL of the peptide digest was injected onto a Symmetry 205 
C18, 180µm x 20mm trapping cartridge (Waters, U.K.). After 5 min washing of the trap 206 
column, peptides were separated on a 75 µm i.d. x 250 mm, 1.7 µm BEH130 C18, column 207 
(Waters, U.K.) using a linear gradient of 5 to 40% B  (buffer A = 0.1% formic acid in H2O, 208 
buffer B = 0.1% formic acid in acetonitrile) over 90 min with a wash to 85% B at a flow rate 209 
of 300 nL/min. All separations were automated, performed on-line and sprayed directly into 210 
the nanospray source of the mass spectrometer. MS experiments were all performed using a 211 
Waters G2-S Synapt HDMS mass spectrometer operating in MSe mode. Data were acquired 212 
from 50 to 2000 m/z with ion mobility enabled using alternate low and high collision energy 213 
(CE) scans. Low CE was 5V and elevated, ramped from 20-40V. The lock mass (Glu-214 
  
fibrinopeptide, (M+2H)+2, m/z = 785.8426) was infused at a concentration of 100 fmol/µL at 215 
300 nl/min and spectra acquired every 13 seconds.  216 
 217 
2.7.2 Identification of proteins from MS spectra 218 
The raw mass spectra were processed using ProteinLynx Global Server Ver 3.0 (enabled 219 
through Symphony pipeline software, Waters, U.K.) to generate a reduced charge state and 220 
de-isotoped precursor lists, with associated product ion mass lists. These mass lists were 221 
searched against the H. influenzae strain 3655 UniProt protein sequence (downloaded June 222 
2016). A maximum of one missed cleavage was allowed for tryptic digestion and the allowed 223 
variable modification was set to contain oxidation of methionine. Carboxyamidomethylation 224 
of cysteine was set as a fixed modification. 225 
 226 
2.8 Statistical analysis 227 
Statistical analyses were performed using GraphPad version 6.04 and unpaired t-tests. Data 228 
reported with a significance ≤0.05 were considered statistically different. Analysis of 229 
identified proteins was corrected for multiple analysis using a false discovery rate (FDR) of 230 
5%. Proteins that were either >1.5 or <0.7 fold changed following NO treatment were 231 
analysed using the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [31,32] to identify 232 
over-represented biological pathways. 233 
 234 
3. RESULTS 235 
3.1 PYRRO-C3D elicits a direct antibacterial effect on planktonic but not biofilm NTHi 236 
Prior to treatment of NTHi, NO release from PYRRO-C3D was first confirmed following 237 
chemical activation by the β-lactamase enzyme penicillinase. Activation of 50 μM PYRRO-238 
C3D resulted in rapid release of NO, reaching a maximum concentration of ~600 nM over 14 239 
minutes, which was followed by a gradual decline over a further 120 minutes (Figure 1b). 240 
  
Treatment of planktonic NTHi cultures with increasing concentrations of PYRRO-C3D 241 
identified that concentrations >50 μM inhibited growth (Figure 2a). However, no reduction 242 
in biofilm viability was observed following PYRRO-C3D treatment at 10 nM - 100 μM over 2 243 
hours (Figure 2b). Treatment of planktonic NTHi with 50 μM PYRRO-C3D released between 244 
48 and 90 nM NO over 15 minutes, with the signal being quenched following addition of the 245 
β-lactamase inhibitor clavulanate (Figure 2c). 246 
 247 
3.2 PYRRO-C3D enhances NTHi biofilm susceptibility to azithromycin 248 
Previous research has shown that NO treatment of biofilms formed by several bacterial 249 
species reduces their tolerance towards antibiotics [33,34]. Treatment of established 72 h 250 
NTHi biofilms with 4 mg/mL azithromycin produced a slight reduction in viable NTHi within 251 
the biofilm (p=0.0019; Figure 3a). Complete killing, however, was not achieved despite the 252 
planktonic MIC for this strain being 0.001 mg/mL (data not shown). Combined treatment 253 
with 4 mg/mL azithromycin and 50 μM PYRRO-C3D resulted in a significant increase in 254 
bacterial killing, where a log-fold reduction in viable cells was observed in the biofilm 255 
population (p=0.0189; Fig. 3a). COMSTAT analysis of the live biofilm population following 256 
confocal imaging indicated that azithromycin alone had little impact on the viable biomass, 257 
whilst combined treatment with PYRRO-C3D produced a significant reduction (p=0.0064; 258 
Figure 3b). Notably, this reduction occurred despite a slight but significant increase in the 259 
live biofilm population occurring following treatment with PYRRO-C3D alone (Figure 3b). 260 
This effect, however, does not appear to be mediated by biofilm dispersal as a significant 261 
drop in the viable supernatant population with PYRRO-C3D alone was observed (p=0.0061; 262 
Figure 3c). No difference between azithromycin treatment alone and combined PYRRO-C3D/ 263 
azithromycin was also observed (p=0.0974; Figure 3c). COMSTAT analysis also showed no 264 
significant difference in biofilm thickness across any of the treatments, suggesting a lack of 265 
biofilm dispersal (Figure 3d). Measurement of biofilm density, assessed by average diffusion 266 
  
distance between live bacteria, revealed that PYRRO-C3D alone increased biofilm density, 267 
whereas treatment with azithromycin had no effect (Figure 4). Combination treatment with 268 
azithromycin did, however, rescind the increase in biofilm density observed when treating 269 
with PYRRO-C3D alone (Figure 4). 270 
 271 
3.3 Response of NTHi biofilms to PYRRO-C3D is NO-mediated 272 
Having established that PYRRO-C3D potentiates the activity of azithromycin against NTHi 273 
biofilms, experiments were next performed to examine whether the effect was NO-274 
mediated. Treatment of biofilms with an equivalent concentration (50 μM) of the 275 
spontaneous NO-donor DEA/NO alone had no effect on biofilm viability (p=1.08; Figure 5a). 276 
In contrast to the PYRRO-C3D/azithromycin combination, no increase in antibiotic efficacy 277 
was observed when DEA/NO was co-administered with azithromycin (p=0.56; Figure 5a). 278 
Treatment with the NO-scavenger cPTIO nullified the increase in azithromycin susceptibility 279 
observed in the presence of PYRRO-C3D (p=0.0001), suggesting that the potentiation effect 280 
is NO-mediated but requires slower, more controlled release of NO than is achievable with 281 
DEA/NO (Figure 5b). Treatment with cephaloram, the parent 1st generation cephalosporin 282 
from which PYRRO-C3D is derived (but lacking an NO donor), also showed no effect on 283 
biofilm viability in the absence or presence of azithromycin, suggesting that the potentiation 284 
response with PYRRO-C3D does not arise from β-lactam-mediated antibacterial activity 285 
(Figure 5a). The β-lactamase inhibitor clavulanate abrogated the potentiation response, 286 
consistent with NO release from PYRRO-C3D requiring β-lactamases (Figure 5b). This finding 287 
was corroborated by the absence of potentiation observed when treating a non-β-lactamase 288 
producing strain (HI5) with PYRRO-C3D and azithromycin (p=0.24), whilst observing a strong 289 
effect with an alternative β-lactamase producing strain HI6 (p<0.0001; Figure 6). 290 
 291 
  
3.4 PYRRO-C3D increases azithromycin susceptibility of NTHi biofilms grown on primary 292 
respiratory epithelial cells 293 
PYRRO-C3D treatment of NTHi biofilms formed on primary respiratory ciliated epithelial cells 294 
at an air-liquid interface (ALI) was used to investigate whether the presence of human host 295 
cells affected the activity of the compound. Lack of NO release from PYRRO-C3D in the 296 
absence of NTHi cells was first confirmed, where NO release was detected only after 297 
introduction of β-lactamase (Figure 7a). Scanning electron microscopy (SEM) was used to 298 
confirm NTHi biofilm formation following 72 h co-culture before proceeding with compound 299 
treatments (Figure 7c). As observed in the in vitro NTHi-only biofilm model, treatment of the 300 
co-cultures with PYRRO-C3D alone had no effect on viability (p=0.41) and treatment with 301 
azithromycin alone resulted in a log-fold reduction (p=0.0007). When used in combination, 302 
azithromycin and PYRRO-C3D produced a significant 2-log-fold reduction in viability relative 303 
to controls (p=0.0026; Figure 7b). 304 
 305 
3.5 Nitric oxide treatment regulates protein expression in NTHi biofilms 306 
Similar to Streptococcus pneumoniae, NTHi lacks proteins possessing the GGDEF, EAL and 307 
HD-GYP domains, which are important in the turnover of the secondary messenger cyclic-di-308 
GMP (c-di-GMP) in response to NO-signals [35]. Label-free proteomic analyses were 309 
therefore performed to probe the mechanism by which NO affects NTHi biofilms. In total, 310 
277 proteins were identified and 127 were expressed in both untreated and 50 μM SNP-311 
treated biofilms. Of these proteins, 16 showed significantly increased expression (5% FDR) 312 
following SNP treatment and were primarily involved in either metabolic or 313 
transcriptional/translational processes (Table 1). KEGG pathway analysis of all proteins 314 
showing increased expression (>1.5 fold change) identified significant enrichment of 315 
ribosome pathways (34 proteins, FDR 1.2x10-28) and glycolysis/gluconeogenesis (9 proteins, 316 
FDR 1.55x10-5). 317 
  
 318 
Uniprot code Protein name gene Ratio treated/untreated
A0A0H3PBJ4 Glucose-specific PTS system enzyme IIA component* crr 24.15 
A0A0H3PK54 Lipoprotein (D-methionine uptake)* metQ 21.52 
A0A0H3PBW8 Phosphoglycerate kinase* pgk 21.00 
A0A0H3PFB4 DNA-directed RNA polymerase subunit alpha* rpoA 16.33 
A0A0H3PJ51 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase* gpmA 13.37 
A0A0H3PG63 Elongation factor G* fusA 12.96 
A0A0H3PMV3 Pyruvate kinase* pykA 11.85 
A0A0H3PI75 Inosine-5'-monophosphate dehydrogenase* guaB 11.41 
A0A0H3PCZ6 L-lactate dehydrogenase* lldD 10.50 
A0A0H3PF36 ATP synthase subunit β atpD 9.97 
A0A0H3PLN7 Pyridoxal 5'-phosphate synthase subunit* pdxS 9.15 
A0A0H3PLM6 Pyruvate dehydrogenase E1 component* aceE 8.25 
A0A0H3PG47 Chaperone protein ClpB clpB 7.89 
A0A0H3PC20 NAD nucleotidase nucA 6.99 
A0A0H3PFF9 Long-chain fatty acid transport protein OMPp1 6.09 
A0A0H3PF51 CTP synthetase pyrG 5.75 
Table 1. Differentially expressed proteins in in vitro NTHi biofilms following SNP (50 μM) 319 
treatment. 5% false discovery rate (FDR), *=significant at 1% FDR. 320 
 321 
4. DISCUSSION 322 
NTHi, a common commensal in the upper respiratory tract, is an opportunistic 323 
pathogen responsible for localised and chronic lung infections associated with lung diseases. 324 
Biofilm formation by NTHi has been identified as playing a key role in both colonisation and 325 
disease, and contributes to ineffective antibiotic treatment [30]. NO has been shown to 326 
signal a dispersal response in several biofilm-forming species, rendering the released 327 
bacteria susceptible to antibiotics [19-21]. The ubiquitous nature of this molecule in human 328 
physiology, however, means that clinical implementation of non-specific NO treatments with, 329 
for example, gaseous NO or spontaneous NO-donors, could result in many side effects [22-330 
  
24]. Cephalosporin-3’-diazeniumdiolates like PYRRO-C3D, designed to target NO release 331 
specifically to bacterial infection sites, present a promising solution to this problem. Our 332 
findings indicate that PYRRO-C3D released low concentrations of NO upon contact with NTHi 333 
and that this release is specifically triggered by β-lactamases, as evidenced by the cessation 334 
of NO release in the presence of the β-lactamase inhibitor clavulanate. These data, and the 335 
lack of NO release when PYRRO-C3D was applied to respiratory epithelial cells in the 336 
absence of NTHi, demonstrates the specificity of the prodrug activation by bacterial cells, an 337 
attribute that would likely reduce the risk of NO-mediated side effects in vivo.  338 
Regulation of the intracellular secondary messenger c-di-GMP plays a pivotal role in 339 
controlling both biofilm formation and dispersal, with increased levels promoting formation 340 
through increased aggregation, extracellular matrix and adhesin production, and reduced 341 
levels signalling a dispersal response [35-37]. C-di-GMP levels are regulated by diguanylate 342 
cyclases (containing GGDEF domains) that are responsible for its synthesis, and 343 
phosphodiesterases (containing HD-GYP and EAL domains) that catalyse degradation [37]. 344 
Increased activity of these phosphodiesterases has been linked to specific external triggers 345 
such as nutrient deprivation, hypoxia and NO [19,38-40]. A putative NO-sensing domain 346 
linked to both GGDEF and EAL domains, termed the NO-induced biofilm dispersal locus A 347 
(NbdA) [40], could be responsible for these downstream effects. However, it is unlikely that 348 
these mechanisms operate in Haemophilus spp. as genome-wide sequencing of NTHi (Rd 349 
KW20), Haemophilus ducreyi, Haemophilus parainfluenzae and Haemophilus parasuis 350 
indicates a lack of proteins possessing GGDEF, EAL or HD-GYP domains [18]. Our data 351 
support this since low concentrations of NO did not appear to reduce the number of viable 352 
cells remaining in biofilms following PYRRO-C3D treatment. However, our proteomic data 353 
suggest that an alternative signalling pathway may be involved.  354 
Proteomic analyses comparing untreated and NO-treated NTHi biofilms 355 
demonstrated increased expression of sixteen proteins involved in metabolic or 356 
  
transcriptional/translational processes. This was confirmed by KEGG pathway analysis of all 357 
differentially expressed proteins, which showed over-representation of ribosome and 358 
glycolysis/gluconeogenesis pathways. A similar response was recently observed in 359 
Streptococcus pneumoniae biofilms, where low dose NO modulated both translation and 360 
metabolism [33]. This is particularly interesting given that S. pneumoniae also lacks the 361 
GGDEF, EAL, and HD-GYP domain-containing proteins associated with the c-di-GMP pathway. 362 
It is possible that this is because both species inhabit the same nasopharyngeal niche, which 363 
not only provides an environment with limited nutrient availability, but also one with low 364 
levels of NO produced by epithelial cells [41]. Of particular interest was the increased 365 
expression of the D-methionine binding lipoprotein MetQ following NO treatment, an amino 366 
acid that has previously been shown to play a role in dispersal of P. aeruginosa, S. auerus 367 
and Staphylococcus epidermidis biofilms [42,43]. Interestingly, MetQ is also linked to a 368 
number of iron chelation/transporter proteins. It is known that iron can interfere with P. 369 
aeruginosa biofilm formation by inhibiting genes associated with biofilm formation, whilst 370 
SapF mediates heme utilisation and is involved in both biofilm persistence and coordination 371 
[44,45]. NO treatment of E. coli has also been shown to inhibit a global regulator (fur) that 372 
uses iron as a co-factor, affecting a wide range of metabolic processes such as the stress 373 
response and iron metabolism [46] and has been implicated in NTHi virulence [47]. 374 
While several studies have shown that NO-mediated dispersal of biofilms reduces 375 
antibiotic tolerance [19-21], the regulation of pneumococcal biofilm metabolism was 376 
recently shown to provide an alternative mechanism for reducing tolerance [33]. As PYRRO-377 
C3D increases the susceptibility of NTHi biofilms to treatment with azithromycin, it is 378 
possible that a similar mechanism to that observed in pneumococcus is also responsible for 379 
reduction in tolerance observed here. Abrogation of the potentiation effect in the presence 380 
of the β-lactamase inhibitor clavulanate and the NO-scavenger cPTIO, in addition to the lack 381 
of response with cephaloram, confirmed that the response to PYRRO-C3D was indeed NO-382 
  
mediated. It is worth noting that treatment of a strain lacking β-lactamase activity failed to 383 
potentiate the activity of azithromycin, suggesting that PYRRO-C3D would likely be effective 384 
only against NTHi biofilms capable of β-lactamase production.  385 
Observing a significant improvement in azithromycin efficacy when used alongside 386 
PYRRO-C3D but not in the presence of an equivalent concentration of the spontaneous NO 387 
donor DEA/NO suggests a bacteria-targeted NO-donor such as PYRRO-C3D would be more 388 
effective in the treatment of biofilm-associated infections. Whilst the half-life of DEA/NO is 389 
around 90 seconds, the release of NO from PYRRO-C3D continues for up to 120 minutes, 390 
suggesting that slow but sustained release is beneficial. Moreover, it was particularly 391 
noteworthy that NTHi biofilm susceptibility to combined PYRRO-C3D and azithromycin 392 
treatment was even more pronounced when co-cultured on primary epithelial cells – a more 393 
physiologically relevant model of biofilm infections in the respiratory tract.  394 
 395 
5. CONCLUSION 396 
In conclusion, this study has shown that the novel NO-donor prodrug PYRRO-C3D is effective 397 
in specifically targeting NO release to β-lactamase producing NTHi biofilms, and that through 398 
modulation of metabolic activity, the compound potentiates the antibacterial activity of 399 
azithromycin. This effect is not seen in the absence of β-lactamase production.  PYRRO-C3D 400 
used in combination with azithromycin thus warrants further investigation as a potential 401 
treatment for chronic, biofilm-based NTHi infections. 402 
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 553 
Figure 1. a) Structure of PYRRO-C3D and NO release mechanism following β-lactam ring 554 
cleavage by β-lactamase. b) NO release from PYRRO-C3D (50 μM in PBS) following activation 555 
with β-lactamase (penicillinase). 556 
 557 
Figure 2. PYRRO-C3D elicits a direct antibacterial effect on planktonic NTHi. a) Planktonic 558 
NTHi growth in the presence of PYRRO-C3D measured by absorbance (OD600; n=4) b) 72 h in 559 
vitro NTHi biofilm viability following 2 h treatment with PYRRO-C3D as measured by CFU 560 
enumeration (n=4). c) NO release from 50 μM PYRRO-C3D in the presence of planktonic 561 
NTHi. The signal was recorded over 15 mins before quenching with the β-lactamase inhibitor 562 
clavulanate (n=2). 563 
 564 
Figure 3. PYRRO-C3D increases NTHi in vitro biofilm susceptibility towards azithromycin 565 
treatment. 72 h NTHi in vitro biofilms treated with 50 μM PYRRO-C3D and 4 mg/ml 566 
azithromycin, both individually and in combination, for 2 h were assessed for viability 567 
through a) CFU enumeration, and b) COMSTAT analysis of live stained bacteria (n=5). c) 568 
Viability of the supernatant population following treatment measured by CFU enumeration, 569 
and d) maximum biofilm thickness measured by confocal microscopy. *p≤0.05, 570 
**p<0.01,***p≤0.001. 571 
 572 
Figure 4. PYRRO-C3D treatment increases NTHi biofilm density. Confocal images of NTHi 573 
biofilms treated with 50 μM PYRRO-C3D and 4 mg/ml azithromycin, both individually and in 574 
combination, for 2 h were processed using COMSTAT software to calculate the average 575 
diffusion distance between live bacteria within biofilms. *p≤0.05. 576 
 577 
Figure 5. Response of NTHi biofilms to PYRRO-C3D is NO-mediated. Viability of 72 h in vitro 578 
NTHi biofilms following 2 h treatment with a) 50 μM DEA/NO, cephaloram and PYRRO-C3D, 579 
and b) 50 μM cPTIO and clavulanate, both individually and in combination with 4 mg/mL 580 
azithromycin for 2 h. Measurement of viability through CFU enumeration *p≤0.05. 581 
Figure 6. NO release from PYRRO-C3D is dependent on NTHi β-lactamase production. 582 
Viability of 72h in vitro biofilms formed by β-lactamase producing (HI6) and non-β-lactamase 583 
  
producing (HI5) NTHi isolates following treatment with 50 μM PYRRO-C3D and 4 mg/ml 584 
azithromycin both individually and in combination for 2 h, as assessed by CFU enumeration 585 
(n=5). **p≤0.01. 586 
Figure 7. PYRRO-C3D treatment increases azithromycin susceptibility of NTHi biofilms 587 
grown on primary respiratory epithelial cells. a) Measurement of NO release from 50 μM 588 
PYRRO-C3D in presence of primary respiratory epithelial cells isolated from grown at air 589 
liquid interface (ALI) before and after activation with 10 units of β-lactamase (penicillinase). 590 
b) Viability of 72 h NTHi biofilms grown at an ALI on primary respiratory epithelial cells 591 
following 2 h treatment with 50 μM PYRRO-C3D and 4 mg/mL azithromycin, both alone and 592 
in combination, as assessed by CFU enumeration (n=5). c) SEM image of a 72 h NTHi biofilm 593 
formed at an ALI on primary respiratory epithelial cells. Scale bar = 10 μM, *p≤0.05, 594 
**p≤0.01. 595 
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